Patents by Inventor Mark C. Benyunes

Mark C. Benyunes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11638756
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: May 2, 2023
    Assignees: Genentech, Inc., Hoffman-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20230000977
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: August 22, 2022
    Publication date: January 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20220362379
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: March 28, 2022
    Publication date: November 17, 2022
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Jayantha Ratnayake, Graham A. Ross
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20210330789
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: July 9, 2021
    Publication date: October 28, 2021
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11077189
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: August 3, 2021
    Assignees: Genentech Inc., Hoffmann La-Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20210015919
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: August 13, 2020
    Publication date: January 21, 2021
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Graham A. Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20200376120
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: August 17, 2020
    Publication date: December 3, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Graham A. Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20200206348
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: February 20, 2020
    Publication date: July 2, 2020
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Jayantha Ratnayake, Graham A. Ross
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20190117769
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.
    Type: Application
    Filed: September 6, 2018
    Publication date: April 25, 2019
    Applicant: Genentech, Inc.
    Inventors: Mark C. Benyunes, Emma L. Clark, Lada Mitchell, Christina H. de Toledo Pelizon, Jayantha Ratnayake, Graham A. Ross
  • ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER
    Publication number: 20180250397
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Application
    Filed: February 28, 2018
    Publication date: September 6, 2018
    Applicants: Genentech, Inc., F. Hoffmann-La Roche AG
    Inventors: Mark C. BENYUNES, Graham Alexander ROSS
  • USES FOR AND ARTICLE OF MANUFACTURE INCLUDING HER2 DIMERIZATION INHIBITOR PERTUZUMAB
    Publication number: 20160175438
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.
    Type: Application
    Filed: March 2, 2016
    Publication date: June 23, 2016
    Applicant: Genentech, Inc.
    Inventors: Sreedhara Alavattam, Lukas C. Amler, Mark C. Benyunes, Emma L. Clark, Christina H. de Toledo Pelizon, Zephania W. Kwong Glover, Lada Mitchell, Jayantha Ratnayake, Graham A. Ross, Ru-Amir Walker
  • THERAPY OF AUTOIMMUNE DISEASE IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR
    Publication number: 20110300136
    Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF?-inhibitor.
    Type: Application
    Filed: May 16, 2011
    Publication date: December 8, 2011
    Applicant: Genentech, Inc.
    Inventor: MARK C. BENYUNES
  • Therapy of autoimmune disease in a patient with an inadequate response to a TNF-? inhibitor
    Patent number: 7976838
    Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF?-inhibitor.
    Type: Grant
    Filed: March 20, 2008
    Date of Patent: July 12, 2011
    Assignee: Genentech, Inc.
    Inventor: Mark C. Benyunes
  • Therapy of autoimmune disease in a patient with an inadequate response to a TNF-? inhibitor
    Patent number: 7708994
    Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF?-inhibitor.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: May 4, 2010
    Assignee: Genentech, Inc.
    Inventor: Mark C. Benyunes
  • THERAPY OF AUTOIMMUNE DISEASE IN A PATIENT WITH AN INADEQUATE RESPONSE TO A TNF-ALPHA INHIBITOR
    Publication number: 20080213280
    Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF?-inhibitor.
    Type: Application
    Filed: March 20, 2008
    Publication date: September 4, 2008
    Applicant: Genentech, Inc.
    Inventor: MARK C. BENYUNES
  • Therapy of autoimmune disease in a patient with an inadequate response to TNF-alpha inhibitor
    Publication number: 20040202658
    Abstract: The present application describes therapy with antagonists which bind to B cell surface markers, such as CD20. In particular, the application describes the use of such antagonists to treat autoimmune disease in a mammal who experiences an inadequate response to a TNF&agr;-inhibitor.
    Type: Application
    Filed: April 6, 2004
    Publication date: October 14, 2004
    Applicant: Genentech, Inc.
    Inventor: Mark C. Benyunes